A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
NCT02130557
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
1. Molecular diagnosis of CP CML of ≤ 6 months (from initial diagnosis).
2. Adequate hepatic, renal and pancreatic function.
3. Age ≥ 18 years.
1. Any prior medical treatment for CML, including tyrosine kinase inhibitors (TKIs), with
the exception of hydroxyurea and/or anagrelide treatment, which are permitted for up
to 6 months prior to study entry (signature of ICF) if suitably approved for use in
the subject's region.
2. Any past or current Central Nervous System (CNS) involvement, including leptomeningeal
leukemia.
3. Extramedullary disease only.
4. Major surgery or radiotherapy within 14 days of randomization.
5. History of clinically significant or uncontrolled cardiac disease.
6. Known seropositivity to human immunodeficiency virus (HIV), current acute or chronic
hepatitis B (hepatitis B surface-antigen positive), hepatitis C, cirrhosis or evidence
of decompensated liver disease. Patients with resolved Hepatitis B can be included.
7. Recent or ongoing clinically significant GI disorder, e.g. Crohn's Disease, Ulcerative
Colitis, or prior total or partial gastrectomy.
8. History of another malignancy within 5 years with the exception of basal cell
carcinoma or cervical carcinoma in situ or stage 1 or 2 cancer that is considered
adequately treated and currently in complete remission for at least l2 months.
9. Current, or recent (within 30 days, or 5 half-lives of investigational product)
participation in other clinical trials of investigational agents and/or containing
interventional procedures deemed contrary to the objectives and conduct of this trial.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Anaheim, California
- Atlanta, Georgia
- Atlanta, Georgia
- Atlanta, Georgia
- Honolulu, Hawaii
- Boise, Idaho
- Boise, Idaho
- Caldwell, Idaho
- Nampa, Idaho
- Chicago, Illinois
- Chicago, Illinois
- Indianapolis, Indiana
- Indianapolis, Indiana
- Lafayette, Louisiana
- Lafayette, Louisiana
- Shreveport, Louisiana
- Shreveport, Louisiana
- Bethesda, Maryland
- Worcester, Massachusetts
- Worcester, Massachusetts
- Ann Arbor, Michigan
- Ann Arbor, Michigan
- Brighton, Michigan
- Canton, Michigan
- Chelsea, Michigan
- Detroit, Michigan
- Grosse Pointe Woods, Michigan
- Grosse Pointe Woods, Michigan
- Edina, Minnesota
- Saint Louis Park, Minnesota
- Stillwater, Minnesota
- Tupelo, Mississippi
- Omaha, Nebraska
- Hackensack, New Jersey
- Hackensack, New Jersey
- Farmington, New Mexico
- Mineola, New York
- Mineola, New York
- New York, New York
- Rochester, New York
- Rochester, New York
- Pinehurst, North Carolina
- Pinehurst, North Carolina
- Cincinnati, Ohio
- West Chester, Ohio
- Charleston, South Carolina
- Charleston, South Carolina
- Charleston, South Carolina
- Easley, South Carolina
- Greenville, South Carolina
- Greenville, South Carolina
- Greer, South Carolina
- Seneca, South Carolina
- Spartanburg, South Carolina
- Houston, Texas
- Murray, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- Seattle, Washington
- Seattle, Washington
- Green Bay, Wisconsin
- Green Bay, Wisconsin
- Green Bay, Wisconsin
- Milwaukee, Wisconsin
- Kogarah, New South Wales
- Box Hill, Victoria
- Ghent,
- Leuven,
- Liège,
- Verviers,
- Moncton, New Brunswick
- Hamilton, Ontario
- Oshawa, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Saskatoon, Saskatchewan
- Quebec,
- Brno,
- Hradec Králové,
- Olomouc,
- Prague,
- Aalborg,
- Aarhus,
- Roskilde,
- Helsinki,
- Strasbourg, NC
- Bordeaux,
- Le Chesnay,
- Nantes cedex 1,
- Nice,
- Nimes,
- Pierre Bénite,
- Poitiers,
- Toulouse cedex 9,
- Bonn, RP
- Aachen,
- Berlin,
- Freiburg,
- Hamburg,
- Jena Lobeda-Ost,
- Magdeburg,
- Budapest,
- Debrecen,
- Györ,
- Kaposvár,
- Szeged,
- Szolnok,
- Haifa,
- Petah-Tikva,
- Catania, CT
- Bergamo,
- Bologna,
- Cagliari,
- Firenze,
- Genova,
- Milano,
- Monza,
- Napoli,
- Reggio Calabria,
- Roma,
- Anyang-si,
- Busan,
- Daegu,
- Jeonju,
- Seoul,
- Seoul,
- Mexico City, DF
- Monterrey, Nuevo LEON
- Amsterdam, Noord Holland
- Amsterdam, Noord-holland
- Bergen,
- Trondheim,
- Gdansk, Pomorskie
- Chorzow,
- Katowice,
- Kraków,
- Lublin,
- Wrocław,
- Łódź,
- Singapore,
- Singapore,
- Singapore,
- Bratislava,
- Johannesburg, Gauteng
- Pretoria, Gauteng
- Pretoria, Gauteng
- Cape Town, Western CAPE
- Badalona, Barcelona
- Madrid, Málaga
- Barcelona,
- Barcelona,
- Madrid,
- Madrid,
- Madrid,
- Salamanca,
- Toledo,
- Valencia,
- Linköping,
- Lund,
- Stockholm,
- Umeå,
- Uppsala,
- Taichung city, R.o.c.
- Tainan City, R.o.c.
- Taipei City, R.o.c.
- Kaohsiung City,
- Muang, Chiang MAI
- Bangkok,
- Bangkok,
- Bangkok,
- Cherkasy,
- Ivano-Frankivsk,
- Khmelnytskyi,
- Kyiv,
- Kyiv,
- Kyiv,
- Kyiv,
- Kyiv,
- Lviv,
- London, Greater London
- Liverpool, Merseyside
- Nottingham, Nottinghamshire
- Oxford, Oxfordshire
- Sheffield, South Yorkshire
- Birmingham, WEST Midlands
- Leeds, WEST Yorkshire
- Cardiff,
- Leicester,
Descriptive Information | |||||||
---|---|---|---|---|---|---|---|
Brief Title ICMJE | A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | ||||||
Official Title ICMJE | A MULTICENTER PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA | ||||||
Brief Summary | Phase 3, 2-arm, randomized, open label trial. Patients will be randomized to receive bosutinib or imatinib for the duration of the study. | ||||||
Detailed Description | The study will be open for enrollment until the planned number of approximately 500 Philadelphia Chromosome Positive (Ph+) patients have been randomized (approximately 250 Ph+ patients in each treatment arm; a total of approximately 530 Ph+ and Ph- patients). All patients will be treated and/or followed for approximately 5 years (240 weeks) after randomization until the study has closed. Patients who discontinue study therapy early due to disease progression or intolerance to study medication will continue to be followed yearly for survival for up to approximately 5 years (240 weeks) after randomization. | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 3 | ||||||
Study Design ICMJE | Allocation: Randomized Masking: None (Open Label) Masking Description: NOTE: Value was Open Label in old format; This study has an open-label design. Although most efficacy studies have a double blind design, this is not feasible in this trial, due to the complexity of the dose reduction and dose escalation schemes with tablets of various sizes, dosage strengths, as well as the number of tablets that would be required daily. However, the opportunity for bias is mitigated by the use of objective outcome measures (MMR, CCyR, CHR). The Investigators will be instructed to ensure that laboratory/pathology personnel are blinded to treatment information. For these reasons, an open-label, randomized study is appropriate. Primary Purpose: Treatment
| ||||||
Condition ICMJE | Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive | ||||||
Intervention ICMJE |
| ||||||
Study Arms ICMJE |
| ||||||
Publications * | Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol. 2018 Jan 20;36(3):231-237. doi: 10.1200/JCO.2017.74.7162. Epub 2017 Nov 1. | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Completed | ||||||
Actual Enrollment ICMJE | 536 | ||||||
Original Estimated Enrollment ICMJE | 530 | ||||||
Actual Study Completion Date ICMJE | April 17, 2020 | ||||||
Actual Primary Completion Date | August 11, 2016 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||||
Sex/Gender ICMJE |
| ||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | Australia, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Norway, Poland, Singapore, Slovakia, South Africa, Spain, Sweden, Taiwan, Thailand, Ukraine, United Kingdom, United States | ||||||
Removed Location Countries | Czech Republic | ||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT02130557 | ||||||
Other Study ID Numbers ICMJE | AV001 2013-005101-31 ( EudraCT Number ) B1871053 ( Other Identifier: Alias Study Number ) | ||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product |
| ||||||
IPD Sharing Statement ICMJE |
| ||||||
Responsible Party | Pfizer | ||||||
Study Sponsor ICMJE | Pfizer | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE |
| ||||||
PRS Account | Pfizer | ||||||
Verification Date | January 2021 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |